HOME > ARCHIVE

ARCHIVE

JPMA to Start Full-Scale Discussions on New Drug Pricing

January 24, 2005
PMDA's Performance in 1st Half of FY2004 Announced

January 24, 2005
BUSINESS NEWS IN BRIEF

January 24, 2005
Designation of Prescription Drugs Proceeding as Planned: Korosho

January 24, 2005
WEBSITE NEWS

January 24, 2005
Full-scale Discussions on Revision of Medical Service Law to Begin in Autumn

January 24, 2005
NEW PRODUCTS

January 24, 2005
METI's Draft Budget Earmarks \3.55 Bil. for Service Industry Creation

January 17, 2005
REGULATORY NEWS IN BRIEF

January 17, 2005
Meet the Leaders (39)

January 17, 2005
WEBSITE NEWS

January 17, 2005
MEETING

January 17, 2005
BULLTEIN

January 17, 2005
New Year's Commentary -1-

January 17, 2005
RESEARCH & DEVELOPMENT NEWS IN BRIEF

January 17, 2005
New Year's Commentary -2-

January 17, 2005
OTC NEWS IN BRIEF

January 17, 2005
Emerging New Therapeutics against Hypercholesterolemia and Atherosclerosis: Lipitor, a Golden Standard?

January 17, 2005
DIAGNOSTIC NEWS IN BRIEF

January 17, 2005
Kyorin to Accelerate Drug Discovery by Acquiring ABI

January 17, 2005

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…